WebApr 7, 2024 · Company, Sectors, Industry Market Research, Stock Quotes, News, Profile, Analysis, Economic Indicators Stock Market Events on 04.07.2024 http://www.regenerx.com/investors
Did you know?
WebDec 31, 2024 · ROCKVILLE, Md., April 11, 2024 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage … WebApr 11, 2024 · Apr 11, 2024, 16:59 ET. ROCKVILLE, Md., April 11, 2024 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a …
WebRegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, … WebMar 17, 2024 · RegeneRx Biopharmaceuticals, Inc. (RegeneRx) is a biopharmaceutical company. The RegeneRx is focused on the development of a therapeutic peptide Thymosin beta 4 (Tb4) for tissue and organ protection, repair, and regeneration. RegeneRx operates in the development and marketing of Tb4, an amino acid peptide. Tb4 is a synthetic copy of …
WebView RegeneRx Biopharmaceuticals Inc RGRX investment & stock information. Get the latest RegeneRx Biopharmaceuticals Inc RGRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. WebApr 5, 2024 · Research RegeneRx Biopharmaceuticals Inc stock. Price, value, ratios, growth and news.
WebApr 11, 2024 · ROCKVILLE, Md., April 11, 2024 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has issued a Letter to Stockholders updating its ongoing operating strategy. The Letter may …
WebJul 1, 2024 · RegeneRx will be issuing to purchasers of common stock Series A Warrants to purchase up to approximately 7.5 million shares of common stock with an exercise price of $0.24 per share, exercisable ... bricklayer\\u0027s 3iWebSep 11, 2013 · 2. Conversion. (a) Optional Conversion. At any time prior to repayment of this Note, the outstanding principal amount of this Note and accrued but unpaid interest on this Note (the “ Conversion Amount ”) may, at the option of the Holder, be voluntarily converted into shares of common stock, $0.001 par value per share (the “ Common Stock ... bricklayer\u0027s 3jWebView the latest market news and prices, and trading information. ... Kazia Therapeutics started at buy with $18 stock price target at Maxim Group. ... RegeneRX Biopharmaceuticals Inc. 0.00%: $15.07M: covid 2nd vaccine booking scotlandWebJun 28, 2024 · On June 28, 2024, RegeneRx Biopharmaceuticals, Inc., a Delaware corporation , entered into a securities purchase ... the Company sold an aggregate of 9,900,000 shares of its common stock (the "Shares") to investors at a price of $0.20 per ... (net exercise) basis. The exercise price under the Warrants is subject to a "full-ratchet ... bricklayer\\u0027s 3lWebFeb 28, 2024 · See the latest Regenerx Biopharmaceuticals Inc stock price (PINX:RGRX), related news, valuation, dividends and more to help you make your investing decisions. covid 2nd booster shot appointmentWebRegeneRX Biopharmaceuticals Inc. options quotes data for sells and puts, including RGRX last price, change and volume. covid 2nd booster shot for under 50WebJan 7, 2011 · For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be … covid 2nd vaccine walk in